Read our latest updates & insights

On 17 September 2025, Formycon announced that Klinge Biopharma, the exclusive holder of the global commercialisation rights for Formycon’s FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), has entered a semi-exclusive licence agreement with French ophthalmology ...

On 17 September 2025, Alteogen announced that the European Commission has approved Eyluxvi® (ALT-L9), biosimilar to Regeneron/Bayer’s Eylea® (aflibercept).  According to Alteogen, Eyluxvi® is the first biosimilar developed by Alteogen through independent in-house research a...

On 17 September 2025, Alvotech filed a petition for post grant review of Regeneron’s patent US12168036 entitled “Methods for Treating Angiogenic Eye Disorders with High Doses of VEGF Receptor Fusion Proteins”.  The patent was granted on 17 December 2024 and relates to metho...

On 17 September 2025, Regeneron filed an application for leave to appeal the decision of Justice Rofe of the Federal Court of Australia refusing to award Regeneron/Bayer a preliminary injunction against Sandoz to prevent the launch of Sandoz’s Afqlir®, biosimilar to Regener...

On 16 September 2025, First Word Pharma reported that Mitsubishi Tanabe Pharma Corporation’s (MTPC) contract with Janssen for co-promotion activities for Janssen’s Stelara® (ustekinumab) in Japan will end on 31 December 2025.

Under the co-promotion agreement, MTPC ha...

On 16 September 2025, STADA announced that Afiveg®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept) received European Commission approval as 40mg/ml solution for injection in pre-filled syringes and vials.  The approval follows a positive opinion from the EMA’s CHMP in...

On 15 September 2025, Bio-Thera and Saudi Arabia-headquartered Jamjoom Pharmaceuticals Factory Company announced they have entered a strategic commercialisation agreement for BAT2306, biosimilar to Novartis’ Cosentyx® (secukinumab).

Under the agreement, Bio-Thera wil...